Fazirsiran sodium is an antisense rnai oligonucleotide commercialized by Takeda Pharmaceutical, with a leading Phase III program in Alpha-1 Antitrypsin Deficiency (A1AD). According to Globaldata, it is involved in 7 clinical trials, of which 2 were completed, and 5 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Fazirsiran sodiums valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Fazirsiran sodium is expected to reach an annual total of $71 mn by 2035 in the US based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Fazirsiran sodium Overview
ARO-AAT is under development for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD). The drug candidate is administered through subcutaneous route. It is a N-acetylgalactosamine-conjugated synthetic double-stranded oligomer specific to serpin family A member 1 gene. It is a follow-on product candidate of ARC-AAT targeting the mutant alpha-1antitrypsin (Z-AAT) protein and is developed based on RNAi platform technology.
Takeda Pharmaceutical Overview
Takeda Pharmaceutical (Takeda) is a global pharmaceutical company primarily engaged in the research, development, production, and commercialization of biopharmaceutical products. It provides treatment for inflammatory bowel disease, acid-related diseases, motility disorders and liver diseases; hemophilia and hereditary bleeding disorders; primary immunodeficiency and multifocal motor neuropathy; major depressive disorder and attention-deficit hyperactivity disorder; and its cancer treatment encompasses multiple myeloma, mantle cell lymphoma, non-small cell lung cancer and chronic myeloid leukemia. While the company markets its pharmaceutical products directly, it also collaborates with marketing alliance partners in worldwide. Takeda operates in various countries worldwide, including Japan, the US, Europe, Latin America, Africa, the Middle East, and the Asia Pacific region. Takeda is headquartered in Tokyo, Japan.
The company reported revenues of (Yen) JPY4,263,762 million for the fiscal year ended March 2024 (FY2024), an increase of 5.9% over FY2023. In FY2024, the companys operating margin was 5.8%, compared to an operating margin of 13.2% in FY2023. In FY2024, the company recorded a net margin of 3.4%, compared to a net margin of 7.9% in FY2023.
For a complete picture of Fazirsiran sodiums valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
